The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share validated methods to evaluate post marketing vaccine performances. The objectives are to identify, pilot test, and disseminate in EU the best study designs to measure, on a real time basis, VE (direct effect) and the VI of vaccination programmes (indirect and overall effect) against laboratory confirmed cases of influenza (types/subtypes) and pneumococcal disease (serotypes), and clinical outcomes. Cost effectiveness analysis will be conducted. Results will allow to understand factors affecting specific VE, the duration of protection of influenza and pneumococcal vaccines, the interaction between vaccines, the role of repeated vaccinations, the occurrence of serotype replacement (pneumococcus); identify vaccine types and brands with low VE; guide the decision of the WHO committees on vaccine strain selection (influenza); provide robust benefit indicators (VE and VI) and cost benefit and effectiveness results; guide vaccination strategies (schedules, doses, boosters). This EU member state collaboration will respond to questions that require studies based on large sample sizes and sharing of expertise that cannot be achieved by one country alone. It will allow the best methods to be used and results to benefit to all EU countries whatever their current public health achievements. Results will be shared with international partners.

Cancer affects 35,000 children, adolescents and young adults (CAYAC) in Europe each year. Current 5-year survival rates are 80%, but the intensive oncological treatments leave CAYAC Survivors (CAYACS) at increased risk of cancer or treatment-induced late health effects, excess morbidity and mortality, and reduced quality of life (QoL). Follow-up care of survivors includes monitoring of cancers, managing all types of late effects, and maintaining overall health. It should also involve considering the needs of families whose functioning has been disrupted by cancer. There are several challenges providing follow-up care for CAYACS and their families: i) it is resource-demanding in an overburdened healthcare system, ii) psychosocial and supportive care needs are often unmet, and iii) access is inequal between European countries. The overall goal of e-QuoL is to use e-health tools to promote Equity in Quality of Life for CAYACS and their families. It will adapt an existing interoperable personalised e-Health tool that can be used alone or as an add-on module to existing tools such as digital survivorship care plans already used in several European countries. Through participatory research, involving CAYACS, families, associations, networks, health institutes, social sciences and humanities researchers and industrial partners from 15 different countries and backgrounds, we will i) identify the unmet needs of CAYAC families and survivors’ (including vulnerable groups: young age and cognitive impairments) and ii) adapt accessible and affordable tools to address these needs. These tools will provide a person-centred approach from medical follow-up, preventive behaviours (e.g. physical activity, nutrition), psychological and social support (e.g. education, employment) to related health information (e.g. on reproductive issues). Ultimately, e-QuoL will improve CAYACS’ QoL by enabling them to actively engage in their care and better self-manage their health and well-being. This action is part of the Cancer Mission cluster of projects on “Quality of Life.

PANDEM-2 implements and demonstrates the most important novel concepts and IT systems to improve the capacity of European pandemic planning and response. Following the PANDEM project (with the same coordinator and many shared partners) and extensive subsequent stakeholder engagement, research and prioritisation, PANDEM-2 meets the real-world needs of public health agencies responsible for pandemics (‘pandemic managers’) and first responders across Europe. PANDEM-2 will enable and demonstrate the capture and integration of pandemic-relevant data from international systems (Go.Data outputs, EWRS, TESSy, etc.), participative surveillance (Influenzanet, Studybugs, etc.), fron laboratory (next generation sequencing) systems and from social media (Twitter, Reddit). This data will be accessible and can be analysed via an online dashboard, designed and built to support the specific needs of pandemic managers. Additional high-priority tools for pandemic spread prediction, visual analytics and resources management, including workforce capacity mapping, will improve preparedness and planning, and enable pandemic managers to be as well positioned as possible for a pandemic when it comes. In order to test the system, while also networking and building relationships across borders and organisations, pandemic managers and first responders from multiple Member States will work together in EU-wise demonstrations, planning and responding to several pandemic scenarios, from Ebola to SARS/MERS CoV, to pandemic influenza. Pandemic communications, highlighted as a key capability gap, will be addressed by resource creation, training and evaluation.

I-MOVE-COVID-19 aims to obtain epidemiological, clinical and virological information about COVID-19 and patients infected with SARS-CoV-2, through provision of a flexible surveillance platform (adaptable to the epidemiological situation), research studies, hypothesis-testing and evaluation of public health interventions (e.g. vaccination, antivirals) in order to contribute to the knowledge base, guide patient management, and inform the public health response. This will be achieved through adaptation and expansion of the existing, long-running, Europe-wide influenza surveillance network (I-MOVE) to include COVID-19. The network includes primary care networks, hospitals, national laboratory reference centres in ten countries. I-MOVE-COVID-19 priority activities and research projects will be selected based on ECDC/WHO input and the proposal’s detailed list. These will be conducted by mobilising an existing large European multidisciplinary network, combining the expertise and resources of groups working in surveillance (epidemiological, clinical, virological), respiratory disease research, and evaluation of vaccines/treatments. Through protocol sharing and pooling European results, questions will be answered which could not be efficiently answered by countries acting alone. I-MOVE-COVID-19 will share study results rapidly and widely with national and international partners and with the wider scientific community and contribute to clinical management of patients and public health preparedness and response to COVID-19.